Cargando…
Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC)
BACKGROUND: Musashi-2 (MSI2) is a member of RNA-binding protein family that regulates mRNA translation of numerous intracellular targets and influences maintenance of stem cell identity. This study assessed MSI2 as a potential clinical biomarker in non-small cell lung cancer (NSCLC). METHODS: The cu...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024834/ https://www.ncbi.nlm.nih.gov/pubmed/33841930 http://dx.doi.org/10.21037/jtd-20-2787 |
_version_ | 1783675391555141632 |
---|---|
author | Topchu, Iuliia Karnaukhov, Nikolai Mazitova, Alexandra Yugai, Veronika Voloshin, Mark Tikhomirova, Mariya Kit, Oleg Frantsiyants, Elena Kharin, Leonid Airapetova, Tamara Ratner, Ekaterina Sabirov, Alexey Abramova, Zinaida Serebriiskii, Iliya Boumber, Yanis Deneka, Alexander |
author_facet | Topchu, Iuliia Karnaukhov, Nikolai Mazitova, Alexandra Yugai, Veronika Voloshin, Mark Tikhomirova, Mariya Kit, Oleg Frantsiyants, Elena Kharin, Leonid Airapetova, Tamara Ratner, Ekaterina Sabirov, Alexey Abramova, Zinaida Serebriiskii, Iliya Boumber, Yanis Deneka, Alexander |
author_sort | Topchu, Iuliia |
collection | PubMed |
description | BACKGROUND: Musashi-2 (MSI2) is a member of RNA-binding protein family that regulates mRNA translation of numerous intracellular targets and influences maintenance of stem cell identity. This study assessed MSI2 as a potential clinical biomarker in non-small cell lung cancer (NSCLC). METHODS: The current study included 40 patients with NSCLC, of whom one presented with stage 1, 14 presented with stage II, 15 presented with stage III, and 10 patients had stage IV. All patients received standard of care treatments. All patient samples were obtained before treatment started. We used immunohistochemical (IHC) approach to measure MSI2 protein expression in matching specimens of normal lung versus tumor tissues, and primary versus metastatic tumors, followed by correlative analysis in relation to clinical outcomes. In parallel, clinical correlative analysis of MSI2 mRNA expression was performed in silico using publicly available datasets (TCGA/ICGC and KM plots). RESULTS: MSI2 protein expression in patient samples was significantly elevated in NSCLC primary tumors versus normal lung tissue (P=0.03). MSI2 elevated expression positively correlated with a decreased progression free survival (PFS) (P=0.026) combined for all stages and with overall survival (OS) at stage IV (P=0.013). Elevated MSI2 expression on RNA level was confirmed in primary tumor versus normal tissue samples in TCGA dataset (P<0.0001), and positively correlated with decreased OS (P=0.02). No correlation was observed between MSI2 expression and age, sex, smoking, and treatment type. CONCLUSIONS: Elevated MSI2 expression in primary NSCLC tumors is associated with poor prognosis and can be used as a novel potential prognostic biomarker in NSCLC patients. Future studies in an extended patient cohort are warranted. |
format | Online Article Text |
id | pubmed-8024834 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-80248342021-04-08 Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC) Topchu, Iuliia Karnaukhov, Nikolai Mazitova, Alexandra Yugai, Veronika Voloshin, Mark Tikhomirova, Mariya Kit, Oleg Frantsiyants, Elena Kharin, Leonid Airapetova, Tamara Ratner, Ekaterina Sabirov, Alexey Abramova, Zinaida Serebriiskii, Iliya Boumber, Yanis Deneka, Alexander J Thorac Dis Original Article BACKGROUND: Musashi-2 (MSI2) is a member of RNA-binding protein family that regulates mRNA translation of numerous intracellular targets and influences maintenance of stem cell identity. This study assessed MSI2 as a potential clinical biomarker in non-small cell lung cancer (NSCLC). METHODS: The current study included 40 patients with NSCLC, of whom one presented with stage 1, 14 presented with stage II, 15 presented with stage III, and 10 patients had stage IV. All patients received standard of care treatments. All patient samples were obtained before treatment started. We used immunohistochemical (IHC) approach to measure MSI2 protein expression in matching specimens of normal lung versus tumor tissues, and primary versus metastatic tumors, followed by correlative analysis in relation to clinical outcomes. In parallel, clinical correlative analysis of MSI2 mRNA expression was performed in silico using publicly available datasets (TCGA/ICGC and KM plots). RESULTS: MSI2 protein expression in patient samples was significantly elevated in NSCLC primary tumors versus normal lung tissue (P=0.03). MSI2 elevated expression positively correlated with a decreased progression free survival (PFS) (P=0.026) combined for all stages and with overall survival (OS) at stage IV (P=0.013). Elevated MSI2 expression on RNA level was confirmed in primary tumor versus normal tissue samples in TCGA dataset (P<0.0001), and positively correlated with decreased OS (P=0.02). No correlation was observed between MSI2 expression and age, sex, smoking, and treatment type. CONCLUSIONS: Elevated MSI2 expression in primary NSCLC tumors is associated with poor prognosis and can be used as a novel potential prognostic biomarker in NSCLC patients. Future studies in an extended patient cohort are warranted. AME Publishing Company 2021-03 /pmc/articles/PMC8024834/ /pubmed/33841930 http://dx.doi.org/10.21037/jtd-20-2787 Text en 2021 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Topchu, Iuliia Karnaukhov, Nikolai Mazitova, Alexandra Yugai, Veronika Voloshin, Mark Tikhomirova, Mariya Kit, Oleg Frantsiyants, Elena Kharin, Leonid Airapetova, Tamara Ratner, Ekaterina Sabirov, Alexey Abramova, Zinaida Serebriiskii, Iliya Boumber, Yanis Deneka, Alexander Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC) |
title | Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC) |
title_full | Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC) |
title_fullStr | Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC) |
title_full_unstemmed | Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC) |
title_short | Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC) |
title_sort | musashi 2 (msi2) expression as an independent prognostic biomarker in non-small cell lung cancer (nsclc) |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024834/ https://www.ncbi.nlm.nih.gov/pubmed/33841930 http://dx.doi.org/10.21037/jtd-20-2787 |
work_keys_str_mv | AT topchuiuliia musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc AT karnaukhovnikolai musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc AT mazitovaalexandra musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc AT yugaiveronika musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc AT voloshinmark musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc AT tikhomirovamariya musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc AT kitoleg musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc AT frantsiyantselena musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc AT kharinleonid musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc AT airapetovatamara musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc AT ratnerekaterina musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc AT sabirovalexey musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc AT abramovazinaida musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc AT serebriiskiiiliya musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc AT boumberyanis musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc AT denekaalexander musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc |